Blog
RSS FeedPosted by Michael Wonder on 26 Jan 2023
More than 400 people set to benefit after NICE approves ground-breaking CAR-T therapy to treat aggressive form of blood cancer
26 January 2023 - Hundreds of people with an aggressive form of lymphoma are set to benefit from the first ...
Posted by Michael Wonder on 04 Dec 2022
Brexucabtagene autoleucel for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukaemia
2 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 23 Nov 2022
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after one systemic treatment
23 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 22 Nov 2022
Tisagenlecleucel for the treatment of patients with follicular lymphoma after two or more therapies
22 November 2022 - NICE is unable to make a recommendation on the use of tisagenlecleucel for the treatment of adults ...
Posted by Michael Wonder on 11 Jul 2021
NICE publishes draft guidance on the use of Libmeldy
9 July 2021 - OTL-200 (Libmeldy) is a gene therapy medicinal product that expresses the human ARSA gene. ...
Posted by Michael Wonder on 25 Feb 2021
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE
25 February 2021 - NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more ...
Posted by Michael Wonder on 24 Feb 2021
Tecartus recommended by NICE
24 February 2021 - Treatment with autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel) is recommended for use within the Cancer Drugs Fund ...
Posted by Michael Wonder on 15 Feb 2021
bluebird bio’s beta thalassaemia gene therapy rejected by NICE
12 February 2021 - bluebird bio’s beta thalassaemia gene therapy betibeglogene autotemcel (beti-cel) has not been recommended by the UK’s ...
Posted by Michael Wonder on 01 Feb 2019
NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma
1 February 2019 - Adults with relapsed or refractory diffuse large B-cell lymphoma will be able to access another revolutionary chimeric ...
Posted by Michael Wonder on 07 Dec 2018
NICE OKs NHS funding for Gilead’s CAR T-cell therapy
7 December 2018 - Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma. ...
Posted by Michael Wonder on 28 Nov 2018
First children set to receive Novartis’ Kymriah
27 November 2018 - The first children to receive Novartis’ Kymriah – a ‘game-changing’ CAR-T therapy for cancer - will ...
Posted by Michael Wonder on 16 Nov 2018
NICE recommends cutting-edge therapy for young people with blood cancer
16 November 2016 - NICE has recommended a pioneering cancer treatment, CART-cell therapy, for people under the age of 25 with ...
Posted by Michael Wonder on 05 Oct 2018
Gilead strikes deal with NHS England on CAR-T Yescarta
5 October 2018 - NHS England claims adult leukaemia access is first in Europe. ...
Posted by Michael Wonder on 19 Sep 2018
NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma
19 September 2018 - The National Institute for Health and Care Excellence has turned down NHS funding for use of ...
Posted by Michael Wonder on 19 Sep 2018
NICE encourages further discussions on Kymriah for adult lymphoma
19 September 2018 - CAR-T is too expensive to recommend as a treatment for adults with lymphoma, NICE says in draft ...